نتائج البحث

Crushing tablets or sprinkling capsules: Implications for clinical strategy and study performance based on BE studies of rivaroxaban and deferasirox.

• Authors : Sus J; Zentiva, k.s., Prague, Czech Republic.; Bosak J

Subjects: Rivaroxaban* ; Drugs, Generic*; Humans

• Source: Clinical and translational science [Clin Transl Sci] 2024 Mar; Vol. 17 (3), pp. e13752.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

Nanoparticle-Mediated Delivery of Deferasirox: A Promising Strategy Against Invasive Aspergillosis.

• Authors : Peppe S; Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA.; Albany Medical College, Washington and Lee University, Lexington, VA 24450, USA.

• Source: Bioengineering (Basel, Switzerland) [Bioengineering (Basel)] 2024 Nov 05; Vol. 11 (11). Date of Electronic Publication: 2024 Nov 05.Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101676056 Publication Model: Electronic Cited Medium: Print ISSN: 2306-5354

تفاصيل العنوان

Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox.

• Authors : Darvishi-Khezri H; Thalassemia Research Center (TRC), Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.; Karami H

Subjects: beta-Thalassemia*/beta-Thalassemia*/beta-Thalassemia*/complications ; beta-Thalassemia*/beta-Thalassemia*/beta-Thalassemia*/drug therapy ; Iron Overload*/Iron Overload*/Iron Overload*/complications

• Source: PloS one [PLoS One] 2024 Jan 12; Vol. 19 (1), pp. e0284267. Date of Electronic Publication: 2024 Jan 12 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Deferasirox causing duodenal ulcer leading to upper gastrointestinal bleed and hemorrhagic shock in a child with beta-thalassemia major.

• Authors : Tresa A; Department of Pediatrics, Bharati Vidyapeeth Medical College and Hospital, Pune, Maharashtra, India.; Shankar GH

Subjects: beta-Thalassemia*/beta-Thalassemia*/beta-Thalassemia*/complications ; beta-Thalassemia*/beta-Thalassemia*/beta-Thalassemia*/drug therapy ; Duodenal Ulcer*/Duodenal Ulcer*/Duodenal Ulcer*/chemically induced

• Source: Indian journal of pharmacology [Indian J Pharmacol] 2023 Sep-Oct; Vol. 55 (5), pp. 335-337.Publisher: Medknow Publications Country of Publication: India NLM ID: 7902477 Publication Model: Print Cited Medium: Internet ISSN: 1998-3751

تفاصيل العنوان

Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia: A 4-year single-center experience.

• Authors : Zengin Ersoy G; Pediatric Hematology Oncology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.; Ayçiçek A

Subjects: Deferasirox/Deferasirox/Deferasirox/*administration & dosage ; Deferasirox/Deferasirox/Deferasirox/*pharmacokinetics ; Thalassemia/Thalassemia/Thalassemia/*blood

• Source: Pediatric hematology and oncology [Pediatr Hematol Oncol] 2021 Sep; Vol. 38 (6), pp. 555-563. Date of Electronic Publication: 2021 Mar 22.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8700164 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.

• Authors : Tripathy I; Department of Paediatric Medicine, Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India.; Panja A

Subjects: Deferasirox*/Deferasirox*/Deferasirox*/adverse effects ; Deferasirox*/Deferasirox*/Deferasirox*/therapeutic use ; Deferiprone*/Deferiprone*/Deferiprone*/adverse effects

• Source: Hemoglobin [Hemoglobin] 2021 Sep; Vol. 45 (5), pp. 296-302. Date of Electronic Publication: 2021 Nov 10.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Fabrication of deferasirox-decorated aptamer-targeted superparamagnetic iron oxide nanoparticles (SPION) as a therapeutic and magnetic resonance imaging agent in cancer therapy.

• Authors : Moghadam SMM; Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, 91775-1436, Iran.; Alibolandi M

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Contrast Media/Contrast Media/Contrast Media/*therapeutic use ; Deferasirox/Deferasirox/Deferasirox/*therapeutic use

• Source: Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry [J Biol Inorg Chem] 2021 Feb; Vol. 26 (1), pp. 29-41. Date of Publisher: Springer Country of Publication: Germany NLM ID: 9616326 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1327

تفاصيل العنوان

Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.

• Authors : Piolatto A; Department of Clinical and Biological Sciences, University of Torino, Torino, Italy. .; Berchialla P

Subjects: Anemia/Anemia/Anemia/*drug therapy ; Deferasirox/Deferasirox/Deferasirox/*administration & dosage ; Iron Overload/Iron Overload/Iron Overload/*drug therapy

• Source: Scientific reports [Sci Rep] 2021 Jun 15; Vol. 11 (1), pp. 12581. Date of Electronic Publication: 2021 Jun 15.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

The effect of deferasirox on endocrine complications in children with thalassemia.

• Authors : Bilgin BK; Department of Pediatric Hematology, Ankara Dışkapı Child Health and Diseases Hematology Oncology Training and Research Hospital, Ankara, Turkey.; Yozgat AK

Subjects: Deferasirox*/Deferasirox*/Deferasirox*/administration & dosage ; Deferasirox*/Deferasirox*/Deferasirox*/adverse effects ; Splenectomy*

• Source: Pediatric hematology and oncology [Pediatr Hematol Oncol] 2020 Sep; Vol. 37 (6), pp. 455-464. Date of Electronic Publication: 2020 Mar 05.Publisher: Informa Healthcare Country of Publication: England NLM ID: 8700164 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review.

• Authors : Babu T; Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.; Panachiyil GM

Subjects: Patient Education as Topic*; Deferasirox/Deferasirox/Deferasirox/*therapeutic use ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*therapeutic use

• Source: Indian journal of pharmacology [Indian J Pharmacol] 2020 Nov-Dec; Vol. 52 (6), pp. 514-519.Publisher: Medknow Publications Country of Publication: India NLM ID: 7902477 Publication Model: Print Cited Medium: Internet ISSN: 1998-3751

تفاصيل العنوان